linjc16/ctgov huggingface dataset:
Modelling Internal Hepatic Movement With an External Abdominal Marker

Study Overview
=================
Brief Summary
-----------------
This study tests the feasibility and reproducibility of patient-specific motion models. These will be used for quantification of safe margin reduction. Patient-specific motion models will be built by post-processing 4D MRI data with non-rigid registration. By comparing these models between visits, model reproducibility will be assessed, and the methodology refined.

Detailed Description
-----------------
The study will use a real time position management (RPM) system for respiratory gating. The RPM system senses the respiration motion of the patient by tracking a pair of reflective markers on a lightweight marker block constructed of a synthetic material. This block is placed on the patient's abdomen. During Radiotherapy, the beam is only switched on at pre-determined phases of respiration. The appropriate phase of respiration is determined by the RPM system. This implies a reliable correlation of external block motion to internal hepatic movement. This correlation is not a simple one, and requires modeling.

Official Title
-----------------
Modelling Internal Hepatic Movement With an External Abdominal Marker Block for Use With a Real Time Position Monitoring System for Respiratory Gating

Conditions
-----------------
Patients With Liver Metastases From Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed adenocarcinoma compatible with primary disease in the colon or rectum Aged 18 years or older Unequivocal contrast-enhanced CT and/or MRI evidence of malignant single or multiple metastases in the liver, metastases at other sites will not be an exclusion criterion WHO performance status 0-2 and life expectancy of at least 12 weeks Informed written consent Exclusion Criteria: Pregnancy or breast feeding Evidence of ascites Patients unable for whatever reason to lie flat Patients unable to give fully informed consent Age< 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The GErman Italian Spanish Takotsubo (GEIST) Registry

Study Overview
=================
Brief Summary
-----------------
GEIST is a multicenter, international observational registry of patients with Takotsubo syndrome. Data regarding the clinical profile (demographic characteristics, clinical presentation, laboratory measures, electrocardiography /echocardiography / coronary angiography parameters, treatment and medication), in-hospital course and complications and short-/long-term outcome are collected prospectively and retrospectively to increase the understanding of the disease.

Detailed Description
-----------------
The open-ended, multicenter, international GEIST registry collects data from patients with Takotsubo syndrome during the index hospitalization and follow-up. Furthermore, long-term outcome data are acquired with structured telephone interviews, in case patients do not undergo regular outpatient visits in the participating study centers. The GEIST registry retrospectively includes data, which have already been collected, and prospectively continues to enroll patients with newly diagnosed Takotsubo syndrome.

Official Title
-----------------
The GErman Italian Spanish Takotsubo (GEIST) Registry

Conditions
-----------------
Takotsubo Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Takotsubo syndrome Exclusion Criteria: Non

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | All-cause mortality (in-hospital, short-term, long-term) | Day 0 | 
| All-cause mortality | All-cause mortality (in-hospital, short-term, long-term) | 3 Month | 
| All-cause mortality | All-cause mortality (in-hospital, short-term, long-term) | 6 Month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-Hospital complications | Cardiogenic shock, pulmonary edema, death, life-threatening arrhythmias, ventricular thrombus formation, right ventricular involvement | Day 0 |
Effects of Preoperative Inspiratory Muscle Training (IMT) in Obese Women Undergoing Open Bariatric Surgery

Study Overview
=================
Brief Summary
-----------------
OBJECTIVE: to determine whether preoperative inspiratory muscle training (IMT) is able to attenuate the impact of surgical trauma on the respiratory muscle strength, in the lung volumes and diaphragmatic excursion in obese women undergoing open bariatric surgery. Therefore, the hypothesis of the present study was that preoperative IMT is able to attenuate the negative effects of surgical trauma on the respiratory muscle strength, in the lung volumes and diaphragmatic excursion, thus reducing the risk of PPC, in obese patients undergoing open bariatric surgery. DESIGN: Randomized controlled trial. SETTING: Meridional Hospital, Cariacica/ES, Brazil. SUBJECTS: Thirty-two obese women undergoing elective open bariatric surgery were randomly assigned to receive preoperative inspiratory muscle training (IMT group) or usual care (control group). MAIN MEASURES: Respiratory muscle strength (maximal inspiratory pressure - MIP and maximal expiratory pressure - MEP), lung volumes and diaphragmatic excursion.

Official Title
-----------------
Effects of Preoperative Inspiratory Muscle Training (IMT) in Obese Women Undergoing Open Bariatric Surgery: Respiratory Muscle Strength, Lung Volumes and Diaphragmatic Excursion

Conditions
-----------------
Preoperative Inspiratory Muscular Training, Bariatric Surgery, Chest Physiotherapy, Postoperative Pulmonary Complications, Obesity

Intervention / Treatment
-----------------
* Other: Inspiratory muscular training - IMT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, Over 18 years of age, No smoking or respiratory disease. Exclusion Criteria: Patients who refused to participate in the steps of the research protocol, Patients with a history of prior abdominal surgery, Patients who were unable to understand and perform the tests properly Patients who refused to sign the Informed Consent Term.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Inspiratory muscular training - IMT|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Relationship Between Vitamin D, Fingernail Thickness and Bone Density

Study Overview
=================
Brief Summary
-----------------
Vitamin D deficiency is common in the elderly and contributes to the increased incidence of falls, hip fracture and depression in this population. An unknown number of elderly have vitamin D resistance resulting in a functional vitamin D deficiency state. Because there are no simple procedures or blood tests that identify vitamin D resistance, its prevalence and contribution to disability in the elderly is unknown. Our inability to screen for this condition precludes our ability to initiate and monitor treatment. Previous studies indicate that fingernail thickness correlates with vitamin D status and may therefore provide a simple cost effective procedure to not only identify patients with vitamin D deficiency but also, those with vitamin D resistance. This procedure may also provide a way to monitor an individual's response to treatment. This study is designed to demonstrate the association between fingernail thickness and vitamin D status.

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Drug: Vitamin D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: females 25-75 years of age with no known bone disorders Exclusion Criteria: history of vertebral fractures or nonvertebral fractures without trauma prescription medications for prevention of osteoporosis (including vitamin D other than multivitamin and estrogen) history of malignancy other than basal cell or squamous cell cancer of the skin use of steroids or anticonvulsants in the 6 months prior to enrollment

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vitamin D|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin D resistance
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).

Official Title
-----------------
An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients With Unresectable Stage III or IV Malignant Melanoma Randomized and Treated With Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels

Conditions
-----------------
Unresectable Stage III or IV Malignant Melanoma

Intervention / Treatment
-----------------
* Drug: Ipilimumab
* Drug: Ipilimumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologic or cytologic diagnosis of unresectable State III or IV malignant melanoma (excluding ocular melanoma); A pre- and post-treatment fresh core or excision tumor biopsy must be provided.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A1<br> | Drug: Ipilimumab<br>* Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.<br>* Other names: (MDX-010);|
| Active Comparator: A2<br> | Drug: Ipilimumab<br>* Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.<br>* Other names: (MDX-010);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Purpose - to identify candidate markers predictive of response and/or serious toxicity to MDX-101 (BMS-734016) |  | on a continuous & ongoing basis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety & tumor response are important secondary objectives. Safety evaluated |  | on a continuous & ongoing basis | 
| Tumor response measured |  | starting @ wk 12 through wk 24. Those continuing on therapy after wk 24 have tumor responses evaluated every 3 months |
Study of Pain Following Removal of Wisdom Teeth With Acute Pulpitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether pulp chamber opening and drainage on wisdom teeth with acute pulpitis before the extraction could reduce postoperative pain so beneficial to patient.

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: inclusion criteria of upper wisdom teeth for the two groups were: vertical eruption; being worthless to be restored; deep caries in the occlusion surface with acute pain; without caries or acute pulpitis in the adjacent second molar Exclusion Criteria: systemic diseases, smokers, inflammation in oral cavity,with history of psychiatric illness,pregnant or lactating females

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 29 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
wisdom teeth, acute pulpitis, extraction, pain, Pain Following Removal of Wisdom Teeth with Acute Pulpitis
Impact of Pyloric Injection of Magnesium Sulfate and Lidocaine Mixture on Outcome After Sleeve Gastrectomy

Study Overview
=================
Brief Summary
-----------------
Postoperative nausea and vomiting is a common adverse effect after sleeve gastrectomy, mostly due to increased intragastric pressure. The present trial aimed to assess the effect of pyloric injection of mixture of magnesium sulfate and lidocaine on postoperative gastric intraluminal pressure and incidence of nausea and vomiting.

Official Title
-----------------
Impact of Pyloric Injection With Magnesium Sulphate and Lidocaine Mixture on Early Postoperative Outcome After Laparoscopic Sleeve Gastrectomy

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Procedure: Pyloric injection of magnesium sulfate and lidocaine mixture
* Procedure: Pyloric injection of saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that aged between18 and 65 years. American Society of Anesthesiologists (ASA) class I - III. Morbidly-obese patients who failed to achieve and maintain a clinically significant weight loss through supervised non-surgical methods for at least 6 months. Surgery was conducted as the first line of treatment in case of patients with BMI ≥ 50 kg/m2 (super obese). Exclusion Criteria: Obesity secondary to endocrine disorders. History of any previous bariatric procedure. Impaired intellectual capacity or major psyciatric disorder. Sweet eaters who would not adopt a change of postoperative eating habits. Lack of willingness and motivation to embrace postoperative lifestyle changes. Substance abuse. Pregnancy or expected pregnancy in the following 12 to 18 months. Severe gastroesophageal reflux disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Pyloric injection of magnesium sulfate and lidocaine mixture<br>After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine | Procedure: Pyloric injection of magnesium sulfate and lidocaine mixture<br>* 100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus<br>|
| Active Comparator: Pyloric injection of saline<br>After sleeve gastrectomy, the pylorus is injected with normal saline | Procedure: Pyloric injection of saline<br>* 5 ml of normal saline is injected in the pylorus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative nausea and vomiting | incidence of postoperative nausea and vomiting as measured by special impact scale | first 24 hours after surgery |
Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases

Study Overview
=================
Brief Summary
-----------------
Interstitial lung diseases (ILD) are a group of diseases affecting the lung interstitium. The lung scarring that occurs in ILD is often irreversible with only mitigating therapy available so far. This study intends to carry out an open, single-armed, phase I/II clinical trial to investigate whether lung stem cells can regenerate damaged lung tissue. During the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. After careful characterization, cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy. The safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.

Official Title
-----------------
Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases

Conditions
-----------------
Interstitial Lung Diseases

Intervention / Treatment
-----------------
* Biological: Lung stem cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with interstitial lung disease Clinically stable Written informed consent signed Exclusion Criteria: Allergic to cell therapy; Patients with serious significant pulmonary infection need anti-infection treatment; Patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3 months; Patients with malignant tumor in the past 5 years; Participated in other clinical trials in the past 3 months; Patients with serious heart disease(NYHA class Ⅲ-Ⅳ) Pregnant or lactating women; The investigator assessed as inappropriate to participate in this clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lung stem cells<br>Patients will receive 0.5-5x10^6 (0.5-5 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy. | Biological: Lung stem cells<br>* Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase of diffusing capacity of the lung for carbon monoxide (DLCO) |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase of total lung capacity (TLC) |  | 24 weeks | 
| Increase in 6 minute walk distance (6MWD) |  | 24 weeks | 
| Life quality: assessed by St. George respiratory questionnaire (SGRQ) |  | 24 weeks |
Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major

Study Overview
=================
Brief Summary
-----------------
Allo-hematopoietic stem cell transplantation(HSCT) is the only way to cure β-thalassemia major at present. To expand donor pool，we developed a haplo-identical HSCT (Hi-HSCT) platform. But in prior Hi-HSCT using high dose post-transplant Cyclophosphamide in patients with leukemia, cytopenia post-transplant often developed, which was considered as a symptom of GVHD. Therefore, the investigators add unrelated umbilical cord blood (UCB) to the Hi-HSCT. It has reported that, as third-party cells, UCB will reduce GVHD.The purpose of this study is to determine whether unrelated UCB following Hi-HSCT can improve outcomes of Hi-HSCT in patients with β-thalassemia major.

Conditions
-----------------
Thalassemia Major

Intervention / Treatment
-----------------
* Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: β-thalassemia major < 18 year old Unrelated umbilical cord blood following Haplo-identical HSCT Exclusion Criteria: ≥ 18 year old HLA- matched related donors Unrelated donor transplants Unrelated umbilical cord blood transplants Severe iron overload in heart by T2*

Ages Eligible for Study
-----------------
Minimum Age: 12 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Hi-HSC-CBT<br> | Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival（OS） | the measure is a composite | 12 months | 
| TM-free survival（TFS） | the measure is a composite | 12 months | 
| Transplant Related Martality (TRM) | the measure is a composite | 12 months | 
| Primary or Secondary Graft Rejection (GR) | the measure is a composite | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The cumulative incidences of acute graft-versus-host disease（GVHD） | the measure is a composite | 12 months | 
| The cumulative incidences of chronic graft vesus host disease (cGVHD) | the measure is a composite | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cord Blood Transplant, Haploidentical HSCT, Thalassemia major